No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Distribution
China Meheco Group Co., Ltd. functions as a pharmaceutical company with a presence across both domestic Chinese and international markets. The enterprise's primary operations involve the import and export of various national Chinese medicines and health-related items, as well as the production and commercial distribution of pharmaceutical and wellness solutions. It also oversees a network of retail pharmacies. The company's extensive product catalog includes bulk pharmaceutical chemicals, such as those from antibiotic fermentation and chemical synthesis, along with finished dosage forms like tablets, injections, and capsules. It supplies a broad range of antibiotics and medications specifically formulated for cardiovascular, cerebrovascular, chronic, and diabetic conditions. Additionally, its offerings encompass antiviral and anti-infectious agents, gastrointestinal remedies, non-steroidal anti-inflammatory drugs, anti-allergic treatments, specialized botanical products, Western medicine preparations, traditional Chinese patent medicines, processed herbal ingredients, medical equipment and supplies, biological products and their raw materials, various chemical raw materials, and nutritional and general healthcare products. Furthermore, China Meheco Group Co., Ltd. engages in the cultivation, processing, warehousing, and transportation of medicinal herbs, including prominent examples such as ginseng, licorice, ephedra, rhubarb, rheum officinale, astragalus membranaceus, scutellaria baicalensis, and fennel. The company, established in 1984, is headquartered in Beijing, China.
www.meheco.comNo one on the platform currently holds 600056.SS.
No tracked institution reports a position in 600056.SS as of their last filing.
No one on the platform has traded 600056.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 4.8% | 6.4% | 13.7% | — | — | — |
| Rev. Growth % | 3.4% | -2.1% | ||||
| Profit Margin % | 1.3% | 1.9% | 2.8% | |||
| Free Cash Flow Margin % | 3.1% | 1.9% | 1.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $29.5B | +14.8% | $0.82 | $0.82–$0.82 | — | 1 |
| 2027 | $32.3B | +9.3% | $1.05 | $1.05–$1.05 | — | 1 |
| 2028 | $32.0B | -0.8% | $0.86 | $0.86–$0.86 | — | 1 |
| 2029 | $33.0B | +3.1% | $0.94 | $0.94–$0.94 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 600056.SSChina Meheco Group Co., Ltd. | $8.83 | -0.56% | $13.2B | — |
| 000028.SZChina National Accord Medicines Corporation Ltd. | $19.63 | -0.86% | $10.5B | — |
| 000739.SZApeloa Pharmaceutical Co.,Ltd | $22.76 | +1.74% | $26.4B | — |
| 002019.SZYifan Pharmaceutical Co., Ltd. | $9.16 | -0.87% | $11.1B | — |
| 002399.SZShenzhen Hepalink Pharmaceutical Group Co., Ltd. |
| $9.37 |
| -0.11% |
| $11.7B |
| — |
| 300529.SZJafron Biomedical Co.,Ltd. | $14.77 | -0.61% | $11.8B | — |
| 300595.SZAutek China Inc. | $9.85 | -0.51% | $8.8B | — |
Source: Financial Modeling Prep · peers by sector/industry